Laboratory Services

Edmonton, Canada

Laboratory Services

Edmonton, Canada
SEARCH FILTERS
Time filter
Source Type

News Article | May 4, 2017
Site: www.businesswire.com

BURLINGTON, N.C. & RENTON, Wash. & ENGLEWOOD, Colo.--(BUSINESS WIRE)--LabCorp® (NYSE:LH) has completed the acquisition of Pathology Associates Medical Laboratories (PAML) from former owners Providence Health & Services (Providence) and Catholic Health Initiatives (CHI). PAML, based in Spokane, Washington, is one of the nation’s premier medical reference laboratories and a healthcare solutions company. With the acquisition of PAML, LabCorp assumes PAML’s ownership interests in several joint ventures: Colorado Laboratory Services (CLS), Kentucky Laboratory Services (KLS), MountainStar Clinical Laboratories (MSCL), PACLAB Network Laboratories (PACLAB) and Tri-Cities Laboratory (TCL). In addition, PAML, as a LabCorp subsidiary, has acquired assets of Alpha Medical Laboratories (Alpha), a former PAML-affiliated joint venture, from its hospital owner. “For over three decades, LabCorp has focused on comprehensive, deeply-engaged relationships with health systems and hospitals,” said David P. King, chairman and chief executive officer, LabCorp. “The acquisition of PAML furthers this strategy and aligns LabCorp with Providence and CHI, two leading, innovative health systems, and deepens our engagement and growth opportunities with a number of important community-based hospitals across multiple states.” LabCorp’s acquisition of PAML represents the first step in completing the transaction. Through 2017 and into 2018, LabCorp will acquire the ownership interests in CLS, KLS and PACLAB from their hospital co-owners. The hospital partners in MSCL and in TCL continue to evaluate future options for their interests in those joint ventures, which may include a sale to LabCorp. PAML and the joint ventures serve customers in Colorado, Idaho, Kentucky, Montana, Oregon, Utah and Washington. Operations of each joint venture, including the menu of services provided, will remain substantially the same until the joint venture transition is complete and ownership has been transferred. There will be no significant changes to operations or services at PAML until all joint venture transactions are complete. The organizations have been working together to plan and implement a smooth, thoughtful transition that maintains continuity of services for patients, hospitals, clients and clinicians, and provides access to the additional capabilities of LabCorp, including access to clinical trials and research through Covance Drug Development, enhanced IT and data analytics, standardized testing platforms and broad patient access. “PAML and its joint ventures have successfully served our communities and many others for years, and we are proud of the high-quality service they have become known for,” said Mike Butler, president of operations, Providence St. Joseph Health. “Together, LabCorp and PAML will continue and expand delivery of high-quality health care services to our patients, hospitals, clients and clinicians.” Through and after the completion of the related joint venture transactions, Providence, CHI and the hospital joint venture owners will continue to provide all existing in-patient hospital laboratory services. PAML, along with LabCorp, will continue to provide the outreach testing services and reference laboratory services currently provided by PAML and the joint ventures. LabCorp and many of the health systems and hospitals that are partnered with PAML are exploring opportunities to collaborate on projects involving LabCorp’s differentiated capabilities. “As part of our mission, CHI is focused on building healthier communities,” said Kevin Lofton, CEO, Catholic Health Initiatives. “We are confident that LabCorp, as PAML’s new owner, will serve the best interests of all who have relied on us to meet their health care needs through comprehensive, high-quality laboratory services.” “This acquisition strengthens LabCorp’s relationships with anchor health systems and expands LabCorp’s geographic presence in important existing markets, allowing LabCorp to support each health system and its existing customers with expanded offerings,” said King. “It was made possible by the mutual commitment among all the parties to provide high-quality, compassionate care, and to improve the health and lives of the patients we serve and the communities where we operate.” Providence Health & Services is committed to improving the health of the communities it serves, especially for those who are poor and vulnerable. In 2016, Providence provided nearly $1.2 billion in community benefit to help meet the needs of its communities, both today and into the future. Providence Health & Services is a part of Providence St. Joseph Health, a family of organizations that includes 50 hospitals, 829 physician clinics, senior services, supportive housing and many other health and educational services. The health system and its partners employ more than 100,000 caregivers serving communities across seven states – Alaska, California, Montana, New Mexico, Oregon, Texas and Washington. Along with Saint Joseph Health, PSJH includes: in Texas, Covenant Health and Covenant Medical Group; in California, Facey Medical Foundation, Hoag Memorial Hospital Presbyterian and St. Joseph Heritage Healthcare; and in Washington, Kadlec Regional Medical Center, Pacific Medical Centers and Swedish Health Services. Catholic Health Initiatives, a nonprofit, faith-based health system formed in 1996 through the consolidation of four Catholic health systems, expresses its mission each day by creating and nurturing healthy communities in the hundreds of sites across the nation where we provide care. The nation’s third-largest nonprofit health system, Englewood, Colorado-based CHI operates in 18 states and comprises 104 hospitals, including four academic medical centers and major teaching hospitals as well as 30 critical-access facilities; community health-services organizations; accredited nursing colleges; home-health agencies; senior living communities; and other facilities and services that span the inpatient and outpatient continuum of care. In fiscal year 2016, CHI provided more than $1.1 billion in financial assistance and community benefit – a 13% increase over the previous year – for programs and services for the poor, free clinics, education and research. Financial assistance and community benefit totaled more than $2 billion with the inclusion of the unpaid costs of Medicare. The health system, which generated operating revenues of $15.9 billion in fiscal year 2016, has total assets of approximately $22.7 billion. LabCorp (NYSE: LH), an S&P 500 company, is a leading global life sciences company that is deeply integrated in guiding patient care, providing comprehensive clinical laboratory and end-to-end drug development services. With a mission to improve health and improve lives, LabCorp delivers world-class diagnostic solutions, brings innovative medicines to patients faster and uses technology to improve the delivery of care. LabCorp reported net revenues of nearly $9.5 billion for 2016 through the contributions of 52,000 employees in approximately 60 countries. To learn more about LabCorp, visit www.labcorp.com, and to learn more about Covance Drug Development, visit www.covance.com. This press release contains forward-looking statements including with respect to estimated 2017 guidance and the impact of various factors on operating and financial results. Each of the forward-looking statements is subject to change based on various important factors, including without limitation, competitive actions in the marketplace, and adverse actions of governmental and other third-party payers. Actual results could differ materially from those suggested by these forward-looking statements. The Company has no obligation to provide any updates to these forward-looking statements even if its expectations change. Further information on potential factors that could affect operating and financial results is included in the Company’s Form 10-K for the year ended December 31, 2016, and subsequent Forms 10-Q, including in each case under the heading risk factors, and in the Company’s other filings with the SEC. The information in this press release should be read in conjunction with a review of the Company’s filings with the SEC including the information in the Company’s Form 10-K for the year ended December 31, 2016, and subsequent Forms 10-Q, under the heading MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.


News Article | May 8, 2017
Site: www.marketwired.com

SEXSMITH, AB--(Marketwired - May 08, 2017) - Angkor Gold Corp. (TSX VENTURE: ANK) ( : ANKOF) ("Angkor" or "the Company") is pleased to announce the results of its ongoing exploration program on the Okalla West project within the Banlung license located in Ratanakiri province, northeast Cambodia. The program is being conducted in cooperation with Blue River Resources Ltd. (TSX VENTURE: BXR). On January 23, 2017, the Company began a test pit exploration program. The near surface samples were analyzed using a screened metallic process and show a north trending gold anomaly at least 320 metres in length and 45 metres in width. This anomaly occupies the southern lobe of the larger 4 km2 surface gold anomaly (see press release of March 6, 2017) and sits on top of clay weathered bedrock. The gold anomaly is located over diorite intruding gabbro. Assay of vein material found in and under the deeply weathered surface layer returned values from 0.18 to 11.5 gpt Au. "The trenching results from Okalla West show good results on surface reflecting a bedrock hosted system just below," said Mike Weeks, CEO of Angkor Gold. "We are excited to continue our exploration on this prospect." The program involved the excavation of pits one metre by two metres. The pits were dug through to the bottom of the deeply weathered surface layer. Samples were collected for pan concentration testing and for metallic screen analysis. An auger hole was drilled from the bottom of each pit as deeply as possible and is designed to identify the underlying geology and sample the bedrock. See the map accompanying this release for pit locations and values. Two 100 kg near surface samples from new pits dug on lines 2 and 5 were collected. The samples were pan concentrated and are being sent to Canada for testing to determine the potential for bulk sampling and test processing. Near surface samples analyzed using a screened metallic process returned values from 0.15 gpt Au to 1.16 gpt Au. Quartz vein material was collected from the pits near or within the north trending anomaly returned highly anomalous results for gold. The vein material displays at least three phases of quartz mineralization. The first phase is massive white quartz and returned 0.18 gpt Au (Sample S103564). The second phase consists of white and grey quartz breccia with abundant pyrite and returned 2.32 gpt Au (Sample S103475). The third phase consisted of grey microcrystalline quartz in breccia with abundant pyrite. It returned 11.5 gpt Au (Sample S103456). Several larger quartz vein float pieces on line 5 (see map) contained visible gold. The multiple phases of quartz and sulphide brecciation and deposition with visible gold indicates a typical structurally controlled "crack and seal" system of gold mineralization. Pit 14 on Line 5 returned the highest metallic screen assay at 2.09 gpt Au. This suggests that there could be multiple parallel fault structures hosting gold veins. During the excavation of the 100kg bulk samples five additional samples of quartz vein float was located directly north of pits 5 and 6 on line 5. Assay results of the samples of auger drilling of bedrock and of the five new quartz vein float samples are pending. Excavation pits consist of lines of pits laid across identified gold in soil anomalies in irregular east/west orientation. Individual pits are approximately 1m wide and 2m long, dug to the depth of the deeply weathered surface layer. Pits are hand dug every 15 m centre. Each pit is sampled from the top to the bottom of the deeply weathered surface material for pan concentration. A second smaller sample was collected and sent for metallic screen analysis. In addition, the bedrock was sampled by an auger hole from the bottom of the pit. The auger holes test as deep as is possible into the weathered bedrock. The deepest so far has been 7.2 metres measured from the surface profile. Auger samples collected immediately beneath the deeply weathered surface layer were sent for gold and multi-element analysis (assays pending). Angkor's QA/QC protocol requires calibration standards and blanks be inserted at a rate of 10 per 100. In addition, periodic checks are run on a selected spectrum of samples at ALS laboratories. All soil and rock samples are submitted to ALS Mineral-Australian Laboratory Services (Cambodia) Co. Ltd for preparation in Phnom Penh, and gold analyses are done by ALS by standard fire assay in their Vientiane laboratories. All other analyses are by ICP-ME and ICP22 in their Australian laboratories. Initial assays use their Au-ICP22 method of standard fire assay with an ICP-Atomic emission spectrometry finish on a 50gm aliquot, which has a detection range of 0.001 to 10 g/t. Check assays use the Au-AA26 method of standard fire assay with an ICP-Atomic absorption spectrometry finish again on a 50gm aliquot, which has a detection limit of 0.01 to 100 g/t. Metallic screen analysis, using their Au-SCR22 method of standard fire assay with an ICP-Atomic absorption spectrometry finish after screening to 75 microns use a 1kg nominal weight sample, with assay of the entire oversize fraction and duplicate assay on 50gm aliquots of the undersize fraction. This last method has been done at the recommendation of the laboratory to avoid over or under-estimating gold grades because coarse gold was suspected. ANGKOR Gold Corp. is a public company listed on the TSX-Venture Exchange and is a leading mineral explorer in Cambodia with a large land package and a first-mover advantage building strong relationships with all levels of government and stakeholders. Under an agreement with Angkor, Blue River Resources Ltd. (TSX VENTURE: BXR) has the right to participate initially in up to a 50% interest of the Banlung exploration license from Angkor Gold Corp., after the completion of a total investment of US$3.5 million in exploration expenditures over a 4-year period. Blue River may then exercise their option on an additional 20% interest of the Banlung tenement through the commission and completion of a bankable feasibility study on the property or portion thereof. Dennis Ouellette, B.Sc, P.Geol., is a member of The Association of Professional Engineers and Geoscientists of Alberta (APEGA #104257) and a Qualified Person as defined by National Instrument 43-101 ("NI 43-101"). He is Angkor's Exploration Manager and has reviewed and approved the technical disclosure in this document. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Certain of the statements made and information contained herein may constitute "forward-looking information." In particular references to the private placement and future work programs or expectations on the quality or results of such work programs are subject to risks associated with operations on the property, exploration activity generally, equipment limitations and availability, as well as other risks that we may not be currently aware of. Accordingly, readers are advised not to place undue reliance on forward-looking information. Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information, whether as a result of new information, future events or otherwise.


News Article | May 23, 2017
Site: www.prweb.com

MedTech For Solutions has announced a partnership with NextGen LifeLabs, a leading equipment provider in the modern ART laboratory, to provide hands-on training utilizing cutting-edge equipment at its recently-opened OvaTools Andrology & Embryology Training Institute in Ft. Lauderdale, Florida. NextGen LifeLabs, a MedTech Group Purchasing vendor, will provide specialized equipment to ensure OvaTools participants receive training on best-in-class laboratory equipment. NextGen supports many of the world’s leading ART laboratories, helping to drive higher rates of success for IVF patients. “We value the partnership and educational support NextGen LifeLabs will provide at our grand opening symposium and at our future training,” added Dr. Kathleen A. Miller, D.H.Sc., Vice President of Laboratory Services, MedTech. “NextGen’s equipment is at the forefront of reproductive medicine, incorporating the best and the brightest new technologies to help ensure laboratory success. We are eager to introduce this innovative equipment to our attendees.” NextGen equipment will be featured at the OvaTools Training Institute’s Grand Opening Symposium, July 8-10th, and all future OvaTools training sessions, with next sessions being August 9-13th and Sept. 13-17th. Equipment that will be present includes: “NextGen is excited to partner with MedTech on the OvaTools Training Institute,” said Steve Strzempek, Technical Sales and Marketing Director, NextGen LifeLabs. “We are confident that this will present a unique opportunity to bring students to an environment with the best staff and a diverse mix of cutting-edge equipment technologies. This will allow for a new generation of embryologists to emerge from the OvaTools Training Institute with the clinical and practical skills needed to grow in their field." Registration is now open for the Grand Opening Symposium and subsequent OvaTools training modules. The sessions will take place in Ft. Lauderdale, Florida. MedTech for Solutions will be providing assistance with travel arrangements and logistics to attendees upon request. Initial demand for the events has been strong, so interested parties are encouraged to register promptly. About NextGen LifeLabs NextGen LifeLabs is a leading provider of specialized equipment, services and support for the modern Assisted Reproductive Technology (ART) laboratory. Working with leading fertility clinics around the country, NextGen LifeLabs provides the most comprehensive solutions for ART laboratories, including equipment sales, installation, service and training, lab design and relocation support. For more information, visit http://nextgenlifelabs.com/. About MedTech For Solutions MedTech For Solutions offers a full range of services to specialty medical practices, with emphasis on ART/IVF practices and laboratories. The MT Laboratory Solutions Division is dedicated to working with practices in the building of new laboratories, as well as, improving clinical outcomes of existing facilities by establishing and implementing state-of-the-art embryology and andrology practices and optimizing ART/IVF laboratory operations. MedTech's Group Purchasing Organization (GPO) provides practices with significant savings for all medical, pharmacy, laboratory, capital equipment and office purchasing needs. Additionally, MedTech offers practice development, recruitment and risk management services. For more information, visit http://www.medtech4solutions.com.


News Article | May 23, 2017
Site: www.businesswire.com

LAS VEGAS--(BUSINESS WIRE)--The Rapaport Breakfast will address the important opportunities and challenges facing the diamond and jewelry industry. Martin Rapaport’s “State of the Diamond Industry” breakfast presentation will take place Wednesday at 8:00 to 10:00 am at the Mandalay Bay South Seas ballroom. “The jewelry industry is undergoing massive change. The traditional role of the retail jeweler is under attack. The internet is no longer just about information, it is now becoming the primary shopping experience for new age consumers. It’s clear that jewelers will have to integrate their traditional added value scenarios with new technology,” said Martin Rapaport. The Rapaport conference will cover three topics. RapNet – Safe Online Diamond Trading, Rapaport Trading – Adjusting to New Market Realities, Rapaport Appraiser Town Hall meeting. Registration is available at www.diamonds.net/JCK2017/Home.aspx, via email announcements@diamonds.net or +1-702-893-9400. The Rapaport Breakfast is free and open to all who register. About the Rapaport Group: The Rapaport Group is a global provider of value added services that support the development of ethical, transparent, competitive and efficient diamond and jewelry markets. Established in 1978, the Rapaport Price List is the primary source of diamond price and market information. Group activities include Rapaport Information Services, Rapaport Magazine, and Diamonds.net, providing research, analysis and news; RapNet – the world’s largest diamond trading network; Rapaport Laboratory Services provides GIA gemological services in India, Belgium and Israel; and Rapaport Trading and Auction Services specializing in recycled diamonds and jewelry. The Group supports over 20,000 clients in 121 countries and has offices in New York, Las Vegas, Antwerp, Ramat Gan, Mumbai, Surat, Dubai and Hong Kong. Additional information is available at www.Diamonds.net.


On Monday, shares in San Diego, California headquartered Organovo Holdings Inc. recorded a trading volume of 549,433 shares. The stock ended the session 0.37% higher at $2.72. The Company's shares are trading 7.62% below their 50-day moving average. Moreover, shares of Organovo, which focuses on developing and commercializing functional human tissues that could be employed in drug discovery and development, biological research, and as therapeutic implants for the treatment of damaged or degenerating tissues and organs, have a Relative Strength Index (RSI) of 42.98. On May 01st, 2017, Organovo announced a collaboration with the University of Virginia (UVA) to develop 3D bioprinted tissues for volumetric muscle loss injury. The research will take place in the laboratory of George J. Christ, Ph.D., professor of biomedical engineering and orthopaedic surgery at UVA. The free research report on ONVO is available at: San Diego, California headquartered DexCom Inc.'s stock closed the day 3.69% lower at $73.40. A total volume of 2.17 million shares was traded, which was above their three months average volume of 937,590 shares. The Company's shares have advanced 22.95% since the start of this year. The stock is trading 6.56% below its 50-day moving average. Additionally, shares of DexCom, which together with its subsidiaries, focuses on the design, development, and commercialization of continuous glucose monitoring systems in the US and internationally, have an RSI of 41.31. On May 03rd, 2017, research firm Canaccord Genuity reiterated its 'Buy' rating on the Company's stock with a decrease of the target price from $95 a share to $90 a share. On May 04th, 2017, DexCom announced that its G5 Mobile CGM System can now be used with Apple Watches throughout Europe by downloading the latest version of the G5 Mobile App - iOS 1.6. By adding Apple Watch as another display device, Europeans living with diabetes have even more options to view their glucose readings and alerts on Dexcom's G5 Mobile CGM System to help better manage their diabetes. The complimentary report on DXCM can be downloaded at: Shares in Madison, New Jersey headquartered Quest Diagnostics Inc. recorded a trading volume of 703,163 shares. The stock ended yesterday's trading session 0.09% higher at $107.19. The Company's shares have advanced 9.53% in the past month, 16.06% in the previous three months, and 17.75% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 7.40% and 19.47%, respectively. Furthermore, shares of Quest Diagnostics, which provides diagnostic testing information and services in the US and internationally, have an RSI of 78.18. On April 26th, 2017, research firm Mizuho reiterated its 'Buy' rating on the Company's stock with an increase of the target price from $110 a share to $115 a share. On May 01st, 2017, Quest Diagnostics announced that its senior Vice President and Chief Information Officer, Lidia L. Fonseca, has received a 2017 Forbes CIO Innovation Award. The award, presented during the Forbes Innovation Summit on April 24th, 2017, recognizes CIOs of multibillion-dollar companies who have demonstrated the ability to generate value through innovation. Visit us today and download our complete research report on DGX for free at: Burlington, North Carolina headquartered Laboratory Corp. of America Holdings' ("LabCorp®") stock finished Monday's session 0.13% lower at $142.19 with a total trading volume of 499,035 shares. The Company's shares have advanced 9.49% over the previous three months and 10.76% since the start of this year. The stock is trading above its 200-day moving average by 4.81%. Additionally, shares of Laboratory Corp., which operates as an independent clinical laboratory company worldwide, have an RSI of 50.73. On May 04th, 2017, LabCorp® has completed the acquisition of Pathology Associates Medical Laboratories (PAML) from former owners Providence Health & Services and Catholic Health Initiatives. With the acquisition, LabCorp assumes PAML's ownership interests in several joint ventures: Colorado Laboratory Services, Kentucky Laboratory Services, MountainStar Clinical Laboratories, PACLAB Network Laboratories, and Tri-Cities Laboratory.  Get free access to your technical report on LH at: Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. SC has not been compensated; directly or indirectly; for producing or publishing this document. The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@stock-callers.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way. SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: info@stock-callers.com Phone number: +44-330-808-3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


News Article | February 23, 2017
Site: www.businesswire.com

NEW YORK--(BUSINESS WIRE)--Rapaport Auctions, the world’s leading recycler of diamonds, opened its melee auction this week with over 120,000 carats of diamonds. The auction offers a broad range of recycled and finely assorted premium quality diamond parcels in all shapes, qualities and sizes. The recycled diamonds are sourced from retailers, pawnshops and refineries from around the world. Viewing is taking place in Rapaport’s New York office from February 21-23 and at AsiaWorld-Expo in Hong Kong from February 28 - March 1. The wide variety of merchandise offered and the opportunity for buyers to purchase such large quantities of diamonds has generated overwhelmingly positive buyer interest. Viewing is by appointment only and limited spaces are available. “We are excited to be auctioning over 120,000 carats of melee diamonds in Hong Kong at one of the largest jewelry shows of the year. The diamond markets have stabilized over the past few months and developed a positive momentum. Prices for larger size diamonds are recovering after an extended period of decline. While demonetization in India drove melee prices down in December, the market is adapting to the new regulations and recovering. We believe the new policies will have a healthy long-term positive impact on the Indian diamond market and international trade. "Markets are in recovery mode with improving U.S. and Chinese demand. However, increased rough supply and tight profitability in the manufacturing and wholesale segments are of concern,” said Ezi Rapaport, Director of Global Trading, Rapaport Group. To participate in Rapaport Auctions, companies are invited to visit: www.rapaportauctions.com, contact Auction Support via email: auctions@rapaport.com or call their local Rapaport office. The Rapaport Group operates in compliance with the U.S. Patriot Act and OFAC regulations. Rapaport Auctions is the leading reseller of diamonds globally and provides an excellent opportunity for the diamond trade to buy and sell diamonds at fair market value cash prices. The large quantities and wide variety of merchandise offered attract competitive bids from a broad range of international buyers. Rapaport Auctions is committed to addressing the needs of the international diamond community for enhanced liquidity while presenting unprecedented buying opportunities. The Rapaport Group is an international network of companies providing added value services that support the development of ethical, transparent, competitive and efficient diamond and jewelry markets. Established in 1978, the Rapaport Price List is the primary source of diamond price and market information. Group activities include Rapaport Information Services, Rapaport Magazine, and Diamonds.net, providing research, analysis and news; RapNet – the world’s largest diamond trading network; Rapaport Laboratory Services provides GIA gemological services in India, Belgium and Israel; and Rapaport Trading and Auction Services specializing in recycled diamonds and jewelry. The Group supports over 20,000 clients in 121 countries and has offices in New York, Las Vegas, Antwerp, Ramat Gan, Mumbai, Surat, Dubai and Hong Kong. Additional information is available at www.Diamonds.net.


BURLINGTON, N.C. & RENTON, Wash. & ENGLEWOOD, Colo.--(BUSINESS WIRE)--Laboratory Corporation of America® Holdings (LabCorp®) (NYSE:LH), Providence Health & Services (Providence) and Catholic Health Initiatives (CHI), today announced that they have entered into a definitive agreement for LabCorp to acquire all of the ownership interest in Pathology Associates Medical Laboratories, LLC, (PAML), one of the nation’s premier medical reference laboratories and a healthcare solutions company jointly owned by Providence and CHI. In addition to PAML, LabCorp will also acquire PAML’s interest in the following joint ventures: Colorado Laboratory Services (CLS), Kentucky Laboratory Services (KLS), MountainStar Clinical Laboratories (MSCL), PACLAB Network Laboratories (PACLAB) and Tri-Cities Laboratory (TCL). “This signature transaction strengthens LabCorp’s relationships with anchor health systems and expands LabCorp’s geographic presence into important markets,” said David P. King, chairman and chief executive officer, LabCorp. “We have always admired the commitment of PAML, its owners and its joint venture partners to providing high-quality, community-based laboratory services. LabCorp shares that same vision and commitment, and is excited to work with these industry-leading health systems and hospitals as partners to continue to provide these services.” Headquartered in Spokane, Washington, PAML and its joint ventures provide laboratory services in California, Colorado, Idaho, Kentucky, Montana, Oregon, Utah and Washington. PAML is an industry leader in joint venture partnerships with community-based hospitals. The transactions involving PAML and the PAML-affiliated joint ventures expand LabCorp’s geographic scope in the Pacific Northwest, Midwest and South. LabCorp currently provides services to several Swedish Medical Center facilities in Seattle, a partner within the Providence system. “We are proud of the high-quality service PAML and its joint ventures have provided,” said Mike Butler, president of operations, chief executive, Providence Health & Services. “We routinely evaluate how to best deliver health care services to the communities we serve and LabCorp will continue to meet the rapidly changing needs of patients and providers.” In addition, the hospital co-owners of CLS, based in Lakewood, Colorado; KLS, based in Lexington, Kentucky; and PACLAB Network Laboratories, based in Renton, Washington; have all agreed to sell their joint venture interests to LabCorp. The hospital partners in MSCL, based in Salt Lake City, Utah, and in TCL, based in Kennewick, Washington, continue to evaluate future options for their ownership of the joint venture, which may include a sale to LabCorp. The hospital co-owner of Alpha Medical Laboratory (Alpha), a PAML-affiliated joint venture based in Coeur d’Alene, Idaho, intends to acquire PAML’s interest in Alpha; after which it will sell the joint venture assets to LabCorp upon final board approval. After the staged transactions are complete, Providence, CHI and the hospital joint venture owners will continue to provide all existing in-patient hospital laboratory services. LabCorp will then continue to provide the outreach testing services and reference laboratory services currently provided by PAML and the joint ventures that are part of the overall transactions. The transactions do not include any PAML joint venture services in California. “As part of our mission, CHI is focused on building healthier communities. This goal guides our business decisions in the constantly changing dynamics and demands of health care today,” said Kevin Lofton, CEO, Catholic Health Initiatives. “We are confident that our selection of LabCorp to be PAML’s new owner will serve the best interests of all who rely on us to meet their health care needs through comprehensive, high quality laboratory services.” The transactions are subject to customary closing conditions, including clearance under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended. The parties anticipate that transaction closings will begin in 2017 and continue into 2018. There will be no changes to operations or services at PAML or the joint ventures until the applicable transaction is complete. The organizations will work together to plan and implement a smooth, thoughtful transition that maintains continuity of services for patients, hospitals, clients and clinicians while providing direct access to the additional capabilities of LabCorp. Other terms of the transactions were not disclosed and no additional information is available at this time. Providence Health & Services is committed to improving the health of the communities it serves, especially for those who are poor and vulnerable. In 2016, Providence provided nearly $1.2 billion in community benefit to help meet the needs of its communities, both today and into the future. Providence Health & Services is a part of Providence St. Joseph Health, a family of organizations that includes 50 hospitals, 829 physician clinics, senior services, supportive housing and many other health and educational services. The health system and its partners employ more than 100,000 caregivers serving communities across seven states – Alaska, California, Montana, New Mexico, Oregon, Texas and Washington. Along with Saint Joseph Health, PSJH includes: in Texas, Covenant Health and Covenant Medical Group; in California, Facey Medical Foundation, Hoag Memorial Hospital Presbyterian and St. Joseph Heritage Healthcare; and in Washington, Kadlec Regional Medical Center, Pacific Medical Centers and Swedish Health Services. Catholic Health Initiatives, a nonprofit, faith-based health system formed in 1996 through the consolidation of four Catholic health systems, expresses its mission each day by creating and nurturing healthy communities in the hundreds of sites across the nation where we provide care. The nation’s third-largest nonprofit health system, Englewood, Colorado-based CHI operates in 18 states and comprises 103 hospitals, including four academic medical centers and major teaching hospitals as well as 30 critical-access facilities; community health-services organizations; accredited nursing colleges; home-health agencies; senior living communities; and other facilities and services that span the inpatient and outpatient continuum of care. In fiscal year 2016, CHI provided more than $1.1 billion in financial assistance and community benefit – a 13% increase over the previous year -- for programs and services for the poor, free clinics, education and research. Financial assistance and community benefit totaled more than $2 billion with the inclusion of the unpaid costs of Medicare. The health system, which generated operating revenues of $15.9 billion in fiscal year 2016, has total assets of approximately $22.7 billion. Laboratory Corporation of America® Holdings (NYSE: LH), an S&P 500 company, is a world leading life sciences company, providing comprehensive clinical laboratory and end-to-end drug development services. With a mission to improve health and improve lives, LabCorp delivers world-class diagnostic solutions, brings innovative medicines to patients faster and uses technology to provide better care. With net revenue in excess of $9 billion in 2016, LabCorp’s 50,000 employees serve clients in 60 countries. To learn more about LabCorp, visit www.labcorp.com, and to learn more about Covance Drug Development, visit www.covance.com. This press release contains forward-looking statements including with respect to LabCorp’s (the Company) estimated 2017 guidance and the impact of various factors on operating and financial results. Each of the forward-looking statements is subject to change based on various important factors, including without limitation, competitive actions in the marketplace and adverse actions of governmental and other third-party payers. Actual results could differ materially from those suggested by these forward-looking statements. The Company has no obligation to provide any updates to these forward-looking statements even if its expectations change. Further information on potential factors that could affect LabCorp’s operating and financial results is included in the Company’s Form 10-K for the year ended December 31, 2015, and subsequent Forms 10-Q, including in each case under the heading risk factors, and in the Company’s other filings with the SEC. The information in this press release should be read in conjunction with a review of the Company’s filings with the SEC including the information in the Company’s Form 10-K for the year ended December 31, 2015, and subsequent Forms 10-Q, under the heading MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.


OKLAHOMA CITY, OK--(Marketwired - February 28, 2017) - Cytovance® Biologics, Inc., a leading full-service contract biopharmaceutical manufacturer, today announced the addition of Dr. John Mott as Vice President of Bioprocess Development. "Cytovance has created a new position within R&D Services responsible for overseeing clinical-stage client projects," said Dr. Jesse McCool, Senior VP of R&D Services, "R&D has developed two distinct service groups to support Cytovance as we grow and build our commercial manufacturing business. We need to drive innovation and continuous improvements across all R&D operations while maintaining phase-appropriate technical approaches for each client's program. John's experience and contributions will be instrumental in fulfilling this strategy." Dr. John Mott has over 30 years' experience with bacterial protein expression and over 15 years' experience with CHO-based protein expression and production. Prior to joining the Cytovance team, John served in research and leadership positions at Pharmacia and Pfizer, and most recently, as Vice President Laboratory Services at Aragen Biosciences. He has led numerous external industry alliances to explore and develop cellular biology technological advancements, as well as established, and provided administrative and scientific oversight for external academic alliances with Universities in the United States and in Europe. John has eight patent applications, 26 publications, and has presented at numerous conferences. A member of the American Society of Microbiology and the New York Academy of Sciences, and a Senior Editor for the Journal of Industrial and Microbiological Biotechnology, John holds a B.A. in Microbiology and a Ph.D. in Genetics, both from the University of Connecticut. "I am honored to be recognized by Darren Head, President and CEO of Cytovance, and by Dr. McCool," said John, "I look forward to working with our executive team and talented employees across the organization while leading the Process and Analytical Development groups. Combining Cytovance's clinical-stage R&D facets, including process and analytical method transfer and development, under one umbrella will improve performance and ultimately provide a better customer experience." Cytovance® Biologics is a biopharmaceutical Contract Development Manufacturing Company (CDMO) specializing in therapeutic protein and antibody production from both mammalian cell culture and microbial fermentation. In addition to its cGMP manufacturing services, the company offers process development, cGMP cell banking, clinical Drug Product fill/finish, and support services from its state-of-the-art Oklahoma City facilities.


News Article | February 21, 2017
Site: www.greencarcongress.com

« €8.5M INTEGRAL thermoelectric generator project with focus on vehicles kicks off in Europe | Main | Infiniti co-developed Gen2 ERS unveiled with all-new Renault Sport R.S.17 F1 racer » Novozymes has introduced the Spirizyme T Portfolio, an advanced suite of glucoamylase enzymes with trehalase and other yield enhancing activities that provide the most total sugar conversion in the industry. Trehalase is an enzyme that converts trehalose, a type of sugar that cannot be fermented to ethanol, to glucose, which is easily fermentable. Trehalose makes up a significant part of the so-called DP2 peak, a measure of residual sugar in an ethanol plant. The more DP2 an ethanol plant can convert; the more ethanol it will produce. Extensive plant trials of Spirizyme T showed that it reduced the amount of residual DP2 by up to 70%, the most in the industry. This would allow a 100 million gallons per year (MGY) plant to convert 11 million pounds of otherwise wasted sugar to approximately 700,000 gallons of additional ethanol per year. At current prices, this would add nearly $1 million in revenue for the plant. Spirizyme T is available in three versions: Novozymes Spirizyme T customers receive an extra layer of service through Novozymes’ Advanced Laboratory Services. A team of specialized scientists examines fermentation samples before and after plant trials to determine DP2 peaks and calculate trehalose conversion. Additional plant data are analyzed to identify areas where customers can operate their plant more efficiently. Customers can get further support from Novozymes’ Bioenergy University, which provides customized education and training to help plant employees advance their skills and knowledge. Spirizyme T will be available in North America immediately, followed by Latin America and Europe later in 2017.


News Article | February 15, 2017
Site: www.prweb.com

Dr.’s Randy and Lydia Muccioli lead Muccioli Dental as a dynamic husband and wife team with elite credentials and experience in their field. The Johns Creek practice is known for their excellence in implants and prosthodontics as well as family and cosmetic dentistry. Their expansive menu of dental services, have propelled Muccioli Dental to be a leading family dental practice in the Johns Creek area. Find Local Doctors recently recognized their success by awarding the practice as a 2017 Top Patient Rated Dentist. Find Local Doctors is a credible online directory that features local dentists and physicians who have earned superior patient reviews across multiple online sources. Muccioli Dental serves patients of all ages with services in general, cosmetic and restorative dentistry. While they are equipped to provide advanced treatments such as Invisalign and porcelain veneers to improve smile aesthetics, they are also uniquely qualified to treat patients with complex restorative needs. Muccioli Dental features an ADA trained and accredited Prosthodontist, Dr. Randy Muccioli. He is able to provide a full menu of esthetic and restorative dental services ranging from custom crowns and implant supported dentures to oral cancer reconstruction and TMD treatments. Each patient of Muccioli Dental is treated in an atmosphere that is calm and relaxing, which includes patient amenities such as a beverage bar, soothing hand treatments, a kids play area and much more. “To be admired and respected by our patients is always the ultimate reward. We are honored to be a Top Patient Rated Dentist for the Johns Creek community, and we will continue to pursue excellence in all we do,” says Dr. Muccioli of Muccioli Dental. More About Dr. Randy Muccioli and Dr. Lydia Muccioli: Dr.’s Randy and Lydia Muccioli are highly trained and both served as dentists in the U.S. Military. Dr. Lydia Muccioli's military dental residency provided a high level of training in the areas of endodontics, periodontics, prosthodontics and surgery. Her services landed her at the Pentagon where she was handpicked to run a dental clinic responsible for treating General Officers of General's Row and the military staff to the White House. Dr. Randy Muccioli also served as a dentist at the Pentagon providing dental services to our nation's top ranking officers and later served as the Chief of Prosthodontics and Laboratory Services and Chief of Dental Forensics at Fort Stewart Georgia. He brings elite skill as a prosthodontics specialist. Muccioli Dental is proud to be one of a handful of dental practices in the greater Atlanta area that has a Prosthodontist on staff. For more information, please visit mdentalsmiles.com or call (678) 389-9955 in Johns Creek.

Loading Laboratory Services collaborators
Loading Laboratory Services collaborators